However, TKIs need to be administered continuously for life to treat CML patients likely due to the scaffolding functions of BCR-ABL that activate compensatory signaling pathways to promote the survival of leukemic stem cells (LSCs) [76, 77]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.